BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moradi-kalbolandi S, Hosseinzade A, Salehi M, Merikhian P, Farahmand L. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. Journal of Pharmacy and Pharmacology 2018;70:841-54. [DOI: 10.1111/jphp.12911] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hosseinzadeh A, Merikhian P, Naseri N, Eisavand MR, Farahmand L. MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02523-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Khodabakhsh F, Merikhian P, Eisavand MR, Farahmand L. Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling. Cancer Cell Int 2021;21:200. [PMID: 33836774 DOI: 10.1186/s12935-021-01899-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cicenas J, Račienė A. Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020. Cancers (Basel) 2021;13:947. [PMID: 33668248 DOI: 10.3390/cancers13050947] [Reference Citation Analysis]
4 Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Breast cancer immunotherapy: Current and novel approaches. Int Immunopharmacol 2021;98:107886. [PMID: 34153663 DOI: 10.1016/j.intimp.2021.107886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhao J, Cui W. Functional Electrospun Fibers for Local Therapy of Cancer. Adv Fiber Mater 2020;2:229-45. [DOI: 10.1007/s42765-020-00053-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
6 Vafaei R, Samadi M, Hosseinzadeh A, Barzaman K, Esmailinejad M, Khaki Z, Farahmand L. Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study. Cancer Cell Int 2022;22:14. [PMID: 35000604 DOI: 10.1186/s12935-021-02398-6] [Reference Citation Analysis]
7 Yang HH, Zhang FF. Magnetic Resonance Imaging Features in Diagnosis of Breast Cancer and Evaluation of Effect of Epidermal Growth Factor Receptor-Targeted Therapy. Biomed Res Int 2022;2022:3127058. [PMID: 35747502 DOI: 10.1155/2022/3127058] [Reference Citation Analysis]
8 Tsuboi S, Jin T. Shortwave-infrared (SWIR) fluorescence molecular imaging using indocyanine green–antibody conjugates for the optical diagnostics of cancerous tumours. RSC Adv 2020;10:28171-9. [DOI: 10.1039/d0ra04710d] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Pérez-Martínez D, Infante YC, Ramírez BS, Rojas G. Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology. Sci Rep 2022;12:12268. [PMID: 35851313 DOI: 10.1038/s41598-022-16411-z] [Reference Citation Analysis]
10 Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, Ueda S, Tokiwa R, Iwata N, Yamasaki A, Hayashi N, Ogura D, Hirotani K, Yoshioka T, Inoue M, Masuko K, Masuko T. Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers. Oncotarget 2020;11:31-45. [PMID: 32002122 DOI: 10.18632/oncotarget.27414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Motamed Fath P, Rahimnejad M, Moradi-kalbolandi S, Ebrahimi Hosseinzadeh B, Jamshidnejad-tosaramandani T. Improvement of cytotoxicity and necrosis activity of ganoderic acid a through the development of PMBN-A.Her2-GA as a targeted nano system. RSC Adv 2021;12:1228-37. [DOI: 10.1039/d1ra06488f] [Reference Citation Analysis]
12 Basaran GS, Bekci H, Baldemir A, Ilgun S, Cumaoglu A. Momordica charantia Seed and Aryl Extracts Potentiate Growth Inhibition and Apoptosis by Dual Blocking of PI3K/AKT and MAPK Pathways as a Downstream Target of EGFR Signaling in Breast Cancer Cells. CNF 2020;16:726-33. [DOI: 10.2174/1573401315666190712214922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Pandya DN, Bhatt NB, Almaguel F, Rideout-Danner S, Gage HD, Solingapuram Sai KK, Wadas TJ. 89Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo. J Nucl Med 2019;60:696-701. [PMID: 30442753 DOI: 10.2967/jnumed.118.216457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Merikhian P, Eisavand MR, Farahmand L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell Int 2021;21:419. [PMID: 34376211 DOI: 10.1186/s12935-021-02107-3] [Reference Citation Analysis]
15 Viswanadh MK, Vikas, Jha A, Reddy Adena SK, Mehata AK, Priya V, Neogi K, Poddar S, Mahto SK, Muthu MS. Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. Nanomedicine 2020;15:2345-67. [DOI: 10.2217/nnm-2020-0167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liu X, Zhang H, Cheng R, Gu Y, Yin Y, Sun Z, Pan G, Deng Z, Yang H, Deng L, Cui W, Santos HA, Shi Q. An immunological electrospun scaffold for tumor cell killing and healthy tissue regeneration. Mater Horiz 2018;5:1082-91. [PMID: 30713696 DOI: 10.1039/c8mh00704g] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 4.8] [Reference Citation Analysis]
17 Hosseini SS, Khalili S, Baradaran B, Bidar N, Shahbazi MA, Mosafer J, Hashemzaei M, Mokhtarzadeh A, Hamblin MR. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. Int J Biol Macromol 2021;167:1030-47. [PMID: 33197478 DOI: 10.1016/j.ijbiomac.2020.11.058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Merikhian P, Darvishi B, Jalili N, Esmailinejad MR, Khatibi AS, Kalbolandi SM, Salehi M, Mosayebzadeh M, Barough MS, Majidzadeh-A K, Yadegari F, Rahbarizadeh F, Farahmand L. Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors. Mol Oncol 2021. [PMID: 34694686 DOI: 10.1002/1878-0261.13123] [Reference Citation Analysis]
19 Metibemu DS, Akinloye OA, Akamo AJ, Ojo DA, Okeowo OT, Omotuyi IO. Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egypt J Med Hum Genet 2019;20. [DOI: 10.1186/s43042-019-0035-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
20 Guo XF, Zhang YY, Kang J, Dou QH, Zhu XF. A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy. J Drug Target 2021;:1-11. [PMID: 34319822 DOI: 10.1080/1061186X.2021.1961791] [Reference Citation Analysis]